NASDAQ:AVEO - AVEO Pharmaceuticals Stock Price, Price Target & More

$2.60 -0.05 (-1.89 %)
(As of 04/20/2018 02:12 PM ET)
Previous Close$2.65
Today's Range$2.56 - $2.67
52-Week Range$0.57 - $4.24
Volume968,544 shs
Average Volume1.86 million shs
Market Capitalization$328.07 million
P/E Ratio-16.25
Dividend YieldN/A
Beta1.32

About AVEO Pharmaceuticals (NASDAQ:AVEO)

AVEO Pharmaceuticals logoAVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for cancer and related diseases. The company's pipeline of product candidates include Tivozanib, a vascular endothelial growth factor (VEGF) to optimize VEGF blockade; Ficlatuzumab, a hepatocyte growth factor (HGF) inhibitory antibody, which has completed Phase II trial that inhibits the activity of the HGF/c-Met pathway; and AV-203, an anti-ErbB3 specific monoclonal antibody that has completed a Phase I dose escalation study. Its development programs also comprise AV-380, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and the AV-353 platform for the potential treatment of pulmonary arterial hypertension. The company has strategic partnerships with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec International GmbH; and Kyowa Hakko Kirin Co., Ltd. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.

Receive AVEO News and Ratings via Email

Sign-up to receive the latest news and ratings for AVEO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:AVEO
CUSIP05358810
Phone617-588-1960

Debt

Debt-to-Equity Ratio-0.45%
Current Ratio1.56%
Quick Ratio1.56%

Price-To-Earnings

Trailing P/E Ratio-16.25
Forward P/E Ratio-9.63
P/E GrowthN/A

Sales & Book Value

Annual Sales$7.58 million
Price / Sales40.77
Cash FlowN/A
Price / CashN/A
Book Value($0.34) per share
Price / Book-7.65

Profitability

EPS (Most Recent Fiscal Year)($0.16)
Net Income$-65,020,000.00
Net Margins-857.96%
Return on EquityN/A
Return on Assets-41.17%

Miscellaneous

Employees19
Outstanding Shares118,870,000

How to Become a New Pot Stock Millionaire

AVEO Pharmaceuticals (NASDAQ:AVEO) Frequently Asked Questions

What is AVEO Pharmaceuticals' stock symbol?

AVEO Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVEO."

How were AVEO Pharmaceuticals' earnings last quarter?

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) issued its quarterly earnings data on Thursday, May, 4th. The biopharmaceutical company reported ($0.12) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.12) by $0.00. The biopharmaceutical company earned $2.53 million during the quarter. View AVEO Pharmaceuticals' Earnings History.

What price target have analysts set for AVEO?

4 brokers have issued 1-year price objectives for AVEO Pharmaceuticals' shares. Their forecasts range from $3.00 to $5.00. On average, they anticipate AVEO Pharmaceuticals' stock price to reach $4.1667 in the next twelve months. View Analyst Ratings for AVEO Pharmaceuticals.

Who are some of AVEO Pharmaceuticals' key competitors?

Who are AVEO Pharmaceuticals' key executives?

AVEO Pharmaceuticals' management team includes the folowing people:
  • Mr. Michael P. Bailey, Pres, CEO & Director (Age 53)
  • Dr. Michael N. Needle M.D., Chief Medical Officer (Age 58)
  • Mr. Matthew D. Dallas, Chief Financial Officer (Age 43)
  • Dr. Emile Farhan Ph.D., VP of Technical Operations
  • Ms. Karuna Rubin J.D., VP of Legal Affairs and Corp. Sec.

Has AVEO Pharmaceuticals been receiving favorable news coverage?

Press coverage about AVEO stock has trended somewhat negative this week, Accern reports. Accern scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. AVEO Pharmaceuticals earned a coverage optimism score of -0.03 on Accern's scale. They also gave news articles about the biopharmaceutical company an impact score of 44.99 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

How do I buy shares of AVEO Pharmaceuticals?

Shares of AVEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AVEO Pharmaceuticals' stock price today?

One share of AVEO stock can currently be purchased for approximately $2.62.

How big of a company is AVEO Pharmaceuticals?

AVEO Pharmaceuticals has a market capitalization of $328.07 million and generates $7.58 million in revenue each year. The biopharmaceutical company earns $-65,020,000.00 in net income (profit) each year or ($0.16) on an earnings per share basis. AVEO Pharmaceuticals employs 19 workers across the globe.

How can I contact AVEO Pharmaceuticals?

AVEO Pharmaceuticals' mailing address is ONE BROADWAY 14TH FLOOR, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-588-1960 or via email at [email protected]


MarketBeat Community Rating for AVEO Pharmaceuticals (AVEO)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  225 (Vote Outperform)
Underperform Votes:  223 (Vote Underperform)
Total Votes:  448
MarketBeat's community ratings are surveys of what our community members think about AVEO Pharmaceuticals and other stocks. Vote "Outperform" if you believe AVEO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVEO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

AVEO Pharmaceuticals (NASDAQ:AVEO) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for AVEO Pharmaceuticals in the last 12 months. Their average twelve-month price target is $4.1667, suggesting that the stock has a possible upside of 60.26%. The high price target for AVEO is $5.00 and the low price target for AVEO is $3.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $4.1667$4.1667$4.1667$3.75
Price Target Upside: 60.26% upside34.41% upside34.41% upside5.06% downside

AVEO Pharmaceuticals (NASDAQ:AVEO) Consensus Price Target History

Price Target History for AVEO Pharmaceuticals (NASDAQ:AVEO)

AVEO Pharmaceuticals (NASDAQ:AVEO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/16/2018B. RileyReiterated RatingBuy$5.00HighView Rating Details
10/6/2017Seaport Global SecuritiesReiterated RatingBuyN/AView Rating Details
8/28/2017Piper JaffrayBoost Price TargetOverweight$3.80 -> $4.50HighView Rating Details
7/13/2017FBR & CoReiterated RatingOutperform$3.00HighView Rating Details
(Data available from 4/20/2016 forward)

Earnings

AVEO Pharmaceuticals (NASDAQ:AVEO) Earnings History and Estimates Chart

Earnings by Quarter for AVEO Pharmaceuticals (NASDAQ:AVEO)

AVEO Pharmaceuticals (NASDAQ:AVEO) Earnings Estimates

2018 EPS Consensus Estimate: ($0.26)
2019 EPS Consensus Estimate: ($0.18)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.06)($0.06)($0.06)
Q2 20181($0.06)($0.06)($0.06)
Q3 20181($0.07)($0.07)($0.07)
Q4 20181($0.07)($0.07)($0.07)
Q1 20191($0.05)($0.05)($0.05)
Q2 20191($0.05)($0.05)($0.05)
Q3 20191($0.04)($0.04)($0.04)
Q4 20191($0.04)($0.04)($0.04)

AVEO Pharmaceuticals (NASDAQ AVEO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017Q3 2017($0.05)($0.02)$6.50 million$4.61 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.10)($0.08)$4.00 million$0.35 millionViewN/AView Earnings Details
5/4/2017Q1 2017($0.12)($0.1160)$2.53 millionViewN/AView Earnings Details
3/22/2017Q4 2016($0.09)($0.11)$0.13 millionViewN/AView Earnings Details
11/4/2016Q3 2016($0.1150)($0.07)$0.99 millionViewN/AView Earnings Details
8/4/2016Q2 2016($0.14)($0.13)$0.19 millionViewN/AView Earnings Details
5/10/2016Q1($0.12)($0.13)$1.00 million$1.20 millionViewN/AView Earnings Details
3/15/2016Q415($0.04)($0.11)$3.60 millionViewN/AView Earnings Details
11/9/2015Q315($0.09)$0.14$15.16 millionViewN/AView Earnings Details
8/10/2015Q2($0.16)($0.10)$0.13 millionViewListenView Earnings Details
5/7/2015Q115($0.27)($0.21)$0.13 millionViewN/AView Earnings Details
3/6/2015Q314($0.28)($0.27)$0.12 millionViewListenView Earnings Details
11/5/2014Q3 2014($0.27)($0.28)$0.33 million$0.87 millionViewN/AView Earnings Details
8/11/2014Q214($0.38)($0.35)$0.35 million$1.85 millionViewN/AView Earnings Details
5/7/2014Q1 2014($0.33)($0.12)$0.38 million$15.29 millionViewN/AView Earnings Details
3/13/2014Q413($0.33)($0.32)$0.14 million$0.3230 millionViewListenView Earnings Details
11/4/2013Q313($0.47)($0.47)$0.23 million$0.32 millionViewN/AView Earnings Details
8/1/2013Q213($0.56)($0.62)$4.30 million$0.32 millionViewN/AView Earnings Details
4/29/2013Q1 2013($0.72)($0.69)$2.52 million$0.3230 millionViewListenView Earnings Details
2/13/2013Q4 2012($0.77)($0.49)$14.49 million$15.53 millionViewN/AView Earnings Details
10/30/2012Q312($0.87)($0.69)$6.57 million$1.02 millionViewN/AView Earnings Details
8/2/2012($0.82)($0.68)ViewN/AView Earnings Details
5/3/2012($0.78)($0.77)ViewN/AView Earnings Details
2/14/2012($0.64)($0.58)ViewN/AView Earnings Details
11/2/2011($0.46)($0.55)ViewN/AView Earnings Details
7/28/2011($0.80)($0.16)ViewN/AView Earnings Details
4/28/2011Q1 2011($0.57)$2.28ViewN/AView Earnings Details
2/16/2011Q4 2010($0.64)($0.30)ViewN/AView Earnings Details
11/4/2010Q3 2010($0.62)($0.60)ViewN/AView Earnings Details
7/29/2010Q2 2010($0.35)($0.50)ViewN/AView Earnings Details
4/29/2010Q1 2010($0.81)($2.27)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

AVEO Pharmaceuticals (NASDAQ:AVEO) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

AVEO Pharmaceuticals (NASDAQ AVEO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.70%
Institutional Ownership Percentage: 51.58%
Insider Trading History for AVEO Pharmaceuticals (NASDAQ:AVEO)
Institutional Ownership by Quarter for AVEO Pharmaceuticals (NASDAQ:AVEO)

AVEO Pharmaceuticals (NASDAQ AVEO) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/10/2018Peter J BarrisMajor ShareholderBuy920,976$2.30$2,118,244.80View SEC Filing  
4/6/2018Ravi ViswanathanMajor ShareholderBuy685,676$2.24$1,535,914.24View SEC Filing  
3/28/2017Equity Opportunities Iv GrowthMajor ShareholderBuy6,000,000$0.50$3,000,000.00View SEC Filing  
1/16/2015Matthew D DallasVPSell3,075$0.82$2,521.50View SEC Filing  
1/7/2015Michael P BaileyCEOSell4,484$0.80$3,587.20View SEC Filing  
1/30/2014Joseph VittiglioSVPSell5,430$1.64$8,905.2034,121View SEC Filing  
3/14/2013David Brannon JohnstonCFOSell1,061$7.34$7,787.74View SEC Filing  
3/7/2013Henri A TermeerDirectorBuy55,499$6.73$373,508.27View SEC Filing  
12/13/2012Ngoc Tuan HaCEOBuy75,000$6.65$498,750.00View SEC Filing  
12/13/2012Robert C YoungDirectorBuy2,371$6.78$16,075.38View SEC Filing  
12/3/2012Robert C YoungDirectorBuy1,250$6.41$8,012.50View SEC Filing  
9/13/2012David Brannon JohnstonCFOSell1,386$10.60$14,691.60View SEC Filing  
8/8/2012Robert C YoungDirectorBuy1,000$8.63$8,630.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

AVEO Pharmaceuticals (NASDAQ AVEO) News Headlines

Source:
DateHeadline
SEC seeks to block ex-Aveo CFOs testimony about consulting counselSEC seeks to block ex-Aveo CFO's testimony about consulting counsel
www.reuters.com - April 19 at 8:16 AM
AVEO Pharmaceuticals (AVEO) Upgraded to "Buy" at Zacks Investment ResearchAVEO Pharmaceuticals (AVEO) Upgraded to "Buy" at Zacks Investment Research
www.americanbankingnews.com - April 16 at 9:17 PM
AVEO Down 7.7% Since Earnings Report: Can It Rebound?AVEO Down 7.7% Since Earnings Report: Can It Rebound?
finance.yahoo.com - April 12 at 5:39 PM
AVEO Pharmaceuticals (AVEO) Presents At H. C. Wainwright Global Life Sciences Conference - SlideshowAVEO Pharmaceuticals (AVEO) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow
seekingalpha.com - April 11 at 5:32 PM
AVEO Pharmaceuticals (AVEO) Buy Rating Reiterated at Piper JaffrayAVEO Pharmaceuticals' (AVEO) Buy Rating Reiterated at Piper Jaffray
www.americanbankingnews.com - April 10 at 10:31 PM
Insider Buying: AVEO Pharmaceuticals, Inc. (AVEO) Major Shareholder Acquires 685,676 Shares of StockInsider Buying: AVEO Pharmaceuticals, Inc. (AVEO) Major Shareholder Acquires 685,676 Shares of Stock
www.americanbankingnews.com - April 10 at 7:30 PM
Peter J. Barris Purchases 920,976 Shares of AVEO Pharmaceuticals, Inc. (AVEO) StockPeter J. Barris Purchases 920,976 Shares of AVEO Pharmaceuticals, Inc. (AVEO) Stock
www.americanbankingnews.com - April 10 at 7:12 PM
Why AVEO Oncology Jumped Higher TodayWhy AVEO Oncology Jumped Higher Today
finance.yahoo.com - April 9 at 5:22 PM
Moving Average Crossover Alert: AVEO Pharmaceuticals, Inc. (AVEO)Moving Average Crossover Alert: AVEO Pharmaceuticals, Inc. (AVEO)
finance.yahoo.com - April 5 at 10:10 AM
Zacks: Brokerages Anticipate AVEO Pharmaceuticals, Inc. (AVEO) to Post -$0.07 EPSZacks: Brokerages Anticipate AVEO Pharmaceuticals, Inc. (AVEO) to Post -$0.07 EPS
www.americanbankingnews.com - April 2 at 9:12 AM
AVEO Pharmaceuticals (AVEO) Downgraded by BidaskClubAVEO Pharmaceuticals (AVEO) Downgraded by BidaskClub
www.americanbankingnews.com - March 30 at 9:17 AM
AVEO Pharmaceuticals, Inc. (AVEO) Receives Average Rating of "Hold" from AnalystsAVEO Pharmaceuticals, Inc. (AVEO) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - March 30 at 1:34 AM
AVEO Pharmaceuticals (AVEO) Lifted to Hold at Zacks Investment ResearchAVEO Pharmaceuticals (AVEO) Lifted to Hold at Zacks Investment Research
www.americanbankingnews.com - March 29 at 11:18 PM
AVEO Pharmaceuticals (AVEO) Presents At Needham And Company 17th Annual Healthcare Conference - SlideshowAVEO Pharmaceuticals (AVEO) Presents At Needham And Company 17th Annual Healthcare Conference - Slideshow
seekingalpha.com - March 29 at 5:30 PM
AVEO Pharmaceuticals (AVEO) Rating Reiterated by B. RileyAVEO Pharmaceuticals (AVEO) Rating Reiterated by B. Riley
www.americanbankingnews.com - March 28 at 12:58 PM
AVEO Pharmaceuticals (AVEO) Upgraded to "Sell" by BidaskClubAVEO Pharmaceuticals (AVEO) Upgraded to "Sell" by BidaskClub
www.americanbankingnews.com - March 26 at 5:58 PM
AVEO Pharmaceuticals (AVEO) Stock Rating Lowered by BidaskClubAVEO Pharmaceuticals (AVEO) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - March 25 at 12:52 AM
AVEO Pharmaceuticals (AVEO) Rating Increased to Sell at BidaskClubAVEO Pharmaceuticals (AVEO) Rating Increased to Sell at BidaskClub
www.americanbankingnews.com - March 24 at 10:58 AM
Options Traders Expect Huge Moves in AVEO Pharmaceuticals (AVEO) StockOptions Traders Expect Huge Moves in AVEO Pharmaceuticals (AVEO) Stock
finance.yahoo.com - March 23 at 5:42 PM
AVEO Oncology Announces Publication of Long-term Follow-up Results from TIVO-1 Extension Study (Study 902) in TKI Refractory RCCAVEO Oncology Announces Publication of Long-term Follow-up Results from TIVO-1 Extension Study (Study 902) in TKI Refractory RCC
finance.yahoo.com - March 21 at 5:38 PM
AVEO Pharmaceuticals (AVEO) Q4 Loss Widens, Shares Down - Yahoo FinanceAVEO Pharmaceuticals (AVEO) Q4 Loss Widens, Shares Down - Yahoo Finance
finance.yahoo.com - March 16 at 8:19 AM
-$0.06 EPS Expected for AVEO Pharmaceuticals, Inc. (AVEO) This Quarter-$0.06 EPS Expected for AVEO Pharmaceuticals, Inc. (AVEO) This Quarter
www.americanbankingnews.com - March 16 at 7:33 AM
Q3 2018 EPS Estimates for AVEO Pharmaceuticals, Inc. Cut by B. Riley (AVEO)Q3 2018 EPS Estimates for AVEO Pharmaceuticals, Inc. Cut by B. Riley (AVEO)
www.americanbankingnews.com - March 15 at 8:15 AM
AVEO Pharmaceuticals, Inc. Forecasted to Earn Q1 2019 Earnings of ($0.05) Per Share (AVEO)AVEO Pharmaceuticals, Inc. Forecasted to Earn Q1 2019 Earnings of ($0.05) Per Share (AVEO)
www.americanbankingnews.com - March 14 at 12:56 PM
BRIEF-Aveo Quarterly Loss Per Share $0.08BRIEF-Aveo Quarterly Loss Per Share $0.08
www.reuters.com - March 13 at 7:17 PM
AVEO Pharmaceuticals (AVEO) Q4 Loss Wider, Revenues MissAVEO Pharmaceuticals (AVEO) Q4 Loss Wider, Revenues Miss
finance.yahoo.com - March 13 at 7:17 PM
AVEO Reports Full Year 2017 Financial Results and Provides Business UpdateAVEO Reports Full Year 2017 Financial Results and Provides Business Update
finance.yahoo.com - March 13 at 8:25 AM
AVEO posts 4Q profitAVEO posts 4Q profit
finance.yahoo.com - March 13 at 8:25 AM
Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of AVEO ... - PR Newswire (press release)Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of AVEO ... - PR Newswire (press release)
www.prnewswire.com - March 9 at 8:20 AM
AVEO Pharmaceuticals (AVEO) Q4 Earnings: Whats in Store?AVEO Pharmaceuticals' (AVEO) Q4 Earnings: What's in Store?
www.msn.com - March 6 at 5:41 PM
AVEO Pharmaceuticals' (AVEO) Q4 Earnings: What's in Store?AVEO Pharmaceuticals' (AVEO) Q4 Earnings: What's in Store?
finance.yahoo.com - March 6 at 5:41 PM
AVEO Oncology to Present at the Cowen and Company 38th Annual Health Care ConferenceAVEO Oncology to Present at the Cowen and Company 38th Annual Health Care Conference
finance.yahoo.com - March 6 at 8:15 AM
Prosight Management LP Purchases New Holdings in AVEO Pharmaceuticals, Inc. (AVEO)Prosight Management LP Purchases New Holdings in AVEO Pharmaceuticals, Inc. (AVEO)
www.americanbankingnews.com - March 5 at 2:54 PM
AVEO Pharmaceuticals, Inc. (AVEO) Receives Consensus Recommendation of "Hold" from BrokeragesAVEO Pharmaceuticals, Inc. (AVEO) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - March 5 at 1:30 AM
Emory University Acquires Shares of 602,883 AVEO Pharmaceuticals, Inc. (AVEO)Emory University Acquires Shares of 602,883 AVEO Pharmaceuticals, Inc. (AVEO)
www.americanbankingnews.com - March 4 at 3:02 PM
EAM Investors LLC Sells 158,839 Shares of AVEO Pharmaceuticals, Inc. (AVEO)EAM Investors LLC Sells 158,839 Shares of AVEO Pharmaceuticals, Inc. (AVEO)
www.americanbankingnews.com - March 3 at 5:40 AM
Zai Lab (ZLAB) vs. AVEO Pharmaceuticals (AVEO) Head-To-Head AnalysisZai Lab (ZLAB) vs. AVEO Pharmaceuticals (AVEO) Head-To-Head Analysis
www.americanbankingnews.com - February 12 at 11:36 AM
Ex-Aveo Pharmaceuticals exec avoids max penalty in SEC fraud caseEx-Aveo Pharmaceuticals exec avoids max penalty in SEC fraud case
www.reuters.com - February 10 at 9:43 AM
AVEO Pharmaceuticals, Inc. (AVEO) Given Consensus Rating of "Hold" by BrokeragesAVEO Pharmaceuticals, Inc. (AVEO) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - February 8 at 1:32 AM
AVEO Announces Appointment of John H. Johnson to Board of DirectorsAVEO Announces Appointment of John H. Johnson to Board of Directors
finance.yahoo.com - February 2 at 9:19 AM
How Much is AVEO Pharmaceuticals Inc’s (NASDAQ:AVEO) CEO Getting Paid?How Much is AVEO Pharmaceuticals Inc’s (NASDAQ:AVEO) CEO Getting Paid?
finance.yahoo.com - January 26 at 9:08 AM
Biotech Forum Daily Digest For January 21st - Seeking AlphaBiotech Forum Daily Digest For January 21st - Seeking Alpha
seekingalpha.com - January 24 at 8:06 AM
Blog Exposure - AVEO Pharma Presents Data from Phase-1b/2 Study of Tivozanib in Patients with Advanced HCCBlog Exposure - AVEO Pharma Presents Data from Phase-1b/2 Study of Tivozanib in Patients with Advanced HCC
finance.yahoo.com - January 23 at 5:26 PM
Ex-Aveo Pharmaceuticals exec fights SEC draconian penalty requestEx-Aveo Pharmaceuticals exec fights SEC 'draconian' penalty request
www.reuters.com - January 18 at 4:24 PM
AVEO Pharmaceuticals, Inc. (AVEO) Receives Average Recommendation of "Hold" from BrokeragesAVEO Pharmaceuticals, Inc. (AVEO) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - January 14 at 1:32 AM
Heres Why AVEO Oncology Rose as Much as 13.7% Today - Motley FoolHere's Why AVEO Oncology Rose as Much as 13.7% Today - Motley Fool
www.fool.com - January 13 at 3:39 PM
Here's Why AVEO Oncology Rose as Much as 13.7% TodayHere's Why AVEO Oncology Rose as Much as 13.7% Today
finance.yahoo.com - January 13 at 11:05 AM
AVEO Oncology to Present at the 36th Annual J.P. Morgan Healthcare ConferenceAVEO Oncology to Present at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 4 at 11:11 AM
SEC seeks penalty, 5-year ban for ex-Aveo Pharmaceuticals execSEC seeks penalty, 5-year ban for ex-Aveo Pharmaceuticals exec
www.reuters.com - January 2 at 9:13 PM
AVEO Oncology Announces Refinanced Debt FacilityAVEO Oncology Announces Refinanced Debt Facility
finance.yahoo.com - January 2 at 9:13 PM

SEC Filings

AVEO Pharmaceuticals (NASDAQ:AVEO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

AVEO Pharmaceuticals (NASDAQ:AVEO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

AVEO Pharmaceuticals (NASDAQ AVEO) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.